Laboratory of Pharmacology and Immunity, Institute of Biological and Health Sciences, Federal University of Alagoas, AC. Simões campus, Maceió, 57072-900, Brazil.
Laboratory of Medicinal Chemistry, Institute of Pharmaceutical Sciences, Federal University of Alagoas, AC. Simões campus, Maceió, 57072-900, Brazil.
Curr Protein Pept Sci. 2024;25(1):12-26. doi: 10.2174/1389203724666230830125102.
Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.
多形性胶质母细胞瘤（GBM）是最常见的影响中枢神经系统（CNS）的癌症类型。它目前占全球诊断出的恶性肿瘤的约 2%，每年报告的新病例约为 29.6 万例。首选的治疗方法包括手术切除、放疗和辅助化疗，这将使患者的生存时间延长 15 个月。新的临床和临床前研究旨在通过提出寻找有效消除癌细胞的新药来改善这一预后，从而避免治疗耐药等问题。在治疗 GBM 方面，有前途的治疗策略之一是抑制磷脂酰肌醇 3-激酶（PI3K）途径，该途径与肿瘤癌变过程密切相关。本综述旨在探讨针对特定疗法的合成或天然药物原型的主要科学研究，这些疗法通过 PI3K 途径靶向人类胶质母细胞瘤。
